First Republic Investment Management, Inc. Invitae Corp Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$24.31 - $33.6 $177,438 - $245,246	-7,299 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$26.09 - $40.4 $17,793 - $27,552	682 Added 10.31%	7,299 $246,000
Q1 2021 May 14, 2021	SELL	$33.06 - $56.93 $329,442 - $567,307	-9,965 Reduced 60.1%	6,617 $253,000
Q4 2020 Feb 16, 2021	BUY	$39.09 - $57.4 $434,250 - $637,656	11,109 Added 202.98%	16,582 $693,000
Q3 2020 Nov 12, 2020	BUY	$28.43 - $44.67 $155,597 - $244,478	5,473 New	5,473 $237,000
Q2 2019 Aug 07, 2019	SELL	$17.37 - $26.27 $195,030 - $294,959	-11,228 Closed	0 $0
Q1 2019 Apr 30, 2019	BUY	$10.65 - $25.75 $8,679 - $20,986	815 Added 7.83%	11,228 $263,000
Q4 2018 Feb 12, 2019	BUY	$9.26 - $16.38 $96,424 - $170,564	10,413 New	10,413 $115,000
Q3 2018 Nov 13, 2018	SELL	$7.54 - $18.31 $78,453 - $190,515	-10,405 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$4.69 - $10.05 $48,799 - $104,570	10,405 New	10,405 $48,000

Others Institutions Holding NVTA

# of Institutions

Shares Held

1.92M

Call Options Held

Put Options Held

View Full List

About Invitae Corp

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

More about NVTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account